http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112915192-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112915192-B |
| titleOfInvention | Use of KP-1 in the preparation of drugs for the treatment of chronic liver disease |
| abstract | The invention relates to the field of medicine, in particular to the use of KP-1 polypeptides in the preparation of medicines for the treatment of chronic liver diseases. It is found in the present invention that the small molecule polypeptide (KP-1) has no obvious toxic and side effects in the mouse animal experiment, and has a very good inhibitory effect on carbon tetrachloride-induced liver fibrosis, and can make the liver interstitial collagen in mice Deposition was significantly reduced, collagen type I and fibronectin were significantly reduced, and the expression of key factors in the TGF-β signaling pathway was significantly down-regulated. Therefore, KP-1 polypeptide is expected to be used for the treatment and/or prevention of chronic liver disease. |
| priorityDate | 2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.